Rare Presentation of Marine-Lenhart Syndrome
DOI:
https://doi.org/10.12970/2310-9874.2013.01.01.1Keywords:
Marine-Lenhart, autoimmune, Graves’ disease, solitary thyroid nodule.Abstract
The combination of autoimmune Graves’ disease with a solitary hot thyroid nodule suppressing the remainder of the thyroid gland is rare. We report a case of Graves’ disease associated with a single hyperfunctioning nodule with suppression of the remaining gland.
A 45 year old male patient with past medical history of autoimmune Graves’ disease with severe ophthalmopathy was referred to endocrine clinic. His symptoms started with dry eyes several years ago without associated hypermetabolic symptoms. Further investigation revealed hyperthyroidism; he was started on methimazole. Thyroid stimulating immunoglobulin was 484 %( reference: <140%, Method: immunoassay). Thyroid scan with I-123 sodium iodide showed uptake of 28.3 percent at 24 hours, and showed a large area of intense activity mid and lower left thyroid lobe with suppression of uptake in the rest of the thyroid gland. Thyroid ultrasound showed a heterogeneous well-defined 1.3x1.0x1.0 cm left mid lower pole nodule. These findings are suggestive of a rare variant of Marine-Lenhart syndrome.
Graves’ hyperthyroidism is thought to be caused by autoantibodies stimulating the TSH receptors. Thyroid nodules associated with Graves’ disease have been reported with the incidence between 25 to 30%, most of which are cold nodules. The incidence of Graves’ disease accompanied by hot nodules ranges from 2.7 to 4.1%.These rare cases of Graves’ disease with accompanying functioning thyroid nodules are known as Marine-Lenhart syndrome. Most reported cases of Marine-Lenhart syndrome are Graves’ disease with multiple hyperfunctioning nodules. Our case represents an unusual variety in which Graves’ disease with a hyperfunctioning solitary nodule was associated with suppression of the remaining gland. Acquired mutations resulting in constitutively activated TSH receptors and the presence of anti TSH receptor autoantibodies might be responsible for the development of Marine-Lenhart syndrome.
References
Cakir M. Marine-Lenhart syndrome. J Natl Med Assoc 2005; 97(7): 1036-38.
Carnell NE, Valente WA. Thyroid nodules in Graves' disease: classification, characterization and response to treatment. Thyroid 1998; 8(8): 647-52. http://dx.doi.org/10.1089/thy.1998.8.647
Vento JA, Slavin JD Jr, Reardon GE, Spencer RP. Graves' disease. Initial presentation with exophthalmos and solitary hot nodule. Clin Nucl Med 1986; 11(6): 404-6. http://dx.doi.org/10.1097/00003072-198606000-00008
Adams DD, Fastier FN, Howie JB, Kennedy TH, Kilpatrick JA, Stewart RD. Stimulation of the human thyroid by infusions of plasma containing LATS protector. J Clin Endocrinol Metab 1974; 39(5): 826-32. http://dx.doi.org/10.1210/jcem-39-5-826
McKenzie JM, Zakarija M. Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. Thyroid 1992; 2(2): 155-9. http://dx.doi.org/10.1089/thy.1992.2.155
Charkes ND. Graves' disease with functioning nodules (Marine-Lenhart syndrome). J Nucl Med 1972; 13(12): 885- 92.
Braga-Basaria M, Basaria S. Marine-Lenhart Syndrome. Thyroid 2003; 13: 991. http://dx.doi.org/10.1089/105072503322511418
Cakir M. Diagnosis of Marine-Lenhart syndrome. Thyroid 2004; 14: 555. http://dx.doi.org/10.1089/1050725041516995
Guerrouj H, Benrais N. Marine-Lenhart syndrome: a case report. Internet J Endocrinol 2007; 3. http://dx.doi.org/10.5580/25f0
Waldherr C, Otte A, Haldemann A, Muller-Brand J. Marine Lenhart syndrome: a case observation upon 18 years. Nuklearmedizin 1999; 38(8): 345-8.
Hernán-Martínez J, Uzcategui M, Corder E, Castillo M, Sostre S, Alicea L. Hyperthyroidism, hyperfunctioning thyroid nodule, and thyroid cancer in a young female: a rare and unusual coexistence. Thyroid: P R Health Sci J 2010; 29(1): 78-82.
Bartalena L. Prevention of Graves' ophthalmopathy. Best Pract Res Clin Endocrinol Metab 2012; 26(3): 371-9. http://dx.doi.org/10.1016/j.beem.2011.09.004